JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

This study is testing a new cell therapy called JY231 — a type of CAR-T therapy where a patient's immune cells are engineered to attack cancer cells carrying the CD19 protein — for people with B-cell lymphoma or leukemia that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are between 18 and 75 years old - Your cancer cells test positive for CD19 (a protein found on B-cells) - You have relapsed or refractory B-cell lymphoma or leukemia, such as follicular lymphoma, marginal zone lymphoma, or diffuse large B-cell lymphoma - You have received prior standard therapies that have not worked **You may NOT be eligible if...** - You have active brain involvement from your cancer - You have significant organ problems (heart, liver, kidney, lungs) - You have active infections or autoimmune conditions requiring treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.